Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2020 Aug 5;110(2):492–506. doi: 10.1016/j.ijrobp.2020.07.2326

Fig. 3.

Fig. 3.

Toxicity evaluation for body weight, liver inflammation, and lung metastasis. (A) Body weights of control (Ctrl) intraperitoneal (IP) phosphate-buffered saline (PBS), Ctrl nanofluidic drug-eluting seed (NDES) PBS, IP CD40/PDL1, and NDES CD40/PDL1 during treatment. Significance annotation of NDES CD40/PDL1 versus IP CD40/PDL1 indicated in the graph. Significance was analyzed by 2-way analysis of variance (ANOVA) (n = 7–8/group). *P ≤ .05. Detailed significance annotation is shown in Table E2. (B) Body weights of Ctrl UnTx, Rad only, IP CD40/PDL1 + Rad, and NDES CD40/PDL1 + Rad, during treatment. Significance annotation of Ctrl UnTx versus IP CD40/PDL1 Rad + indicated in the graph. Significance was analyzed by 2-way ANOVA (n = 7–8/group), **P ≤ .01, ****P ≤ .0001. Detailed significance annotation is shown in Table E2. (C) Liver inflammation scoring by pathologist. (D) Representative figures of liver inflammation of each group.